Dung-Fang Lee


McGovern Medical School The University of Texas Health Science Center at Houston


Assistant Professor, Department of Integrative Biology and Pharmacology


B.S. Chemical Engineering (1994)
National Tsing Hua University
Hsinchu, Taiwan
M.S. Radiobiology (1996)
National Tsing Hua University
Hsinchu, Taiwan
Ph.D. Cancer Biology (2008)
The University of Texas Graduate School of Biomedical Sciences at Houston,
Houston, TX
Postdoctoral Fellow (06/2008-02/2016)
Developmental and Regenerative Biology
Black Family Stem Cell Institute
Icahn School of Medicine at Mount Sinai
New York, NY


NHRI Travel Fellowship Award (2002)
MDACC Trainee Recognition Award (2004, 2006)
DoD Breast Cancer Research Program Predoctoral Traineeship Award (2004-2007)
UT-GSBS T.C. Hsu Endowed Memorial Scholarship (2006)
UT-GSBS Andrew Sowell-Wade Huggins Scholarship (2006)
UT-GSBS President’s Research Scholarship (2007)
UT-GSBS Travel Award (2008)
MDACC Alfred Knudson Jr. Outstanding Dissertation Award (2008)
ISSCR Travel Award (2009 and 2011)
ISSCR Poster Award (2009)
NYSCF-Druckenmiller Postdoctoral Fellowship (2009-2011)
NIH K99/R00 NIH Pathway to Independence Award (2014-Present)
ISMMS Postdoc Recognition Award (2014)
CPRIT Scholar in Cancer Research (2016-Present)
Nominated by UTHealth for the Pew Biomedical Scholar Award (2018)
Nominated by UTHealth for Ted Nash Long Life Foundation Grant (2018)
Rolanette and Berdon Lawrence Research Award, Rolanette and Berdon Lawrence
Bone Disease Program of Texas (2019)


Dissecting and Targeting RB1-mutant Osteosarcoma
PI: Dung-Fang Lee, Ph.D.
Role: PI (30% effort)
$295,124/year direct costs
The Genetic Landscape of Human Tooth Agenesis
PI: Ariadne Letra, D.D.S., M.S., Ph.D. (UTHealth)
Role: co-Investigator (2% effort)
$2,667/year direct costs
Exploiting RB1 Mutation Associated Bone Malignancies with an hiPSC Approach
P.I.: Dung-Fang Lee
Role: PI
$166,667/year direct costs
The Epitranscriptomic Pathway is a Therapeutic Vulnerability in p53-mutant Osteosarcoma
PI: Dung-Fang Lee, Ph.D.
Role: PI (5% effort)
Pablove Foundation
$50,000/year direct costs
Dissect mutant p53 driven osteosarcomagenesis with LFS hPSCs
PI: Dung-Fang Lee, Ph.D. and Ruiying Zhao, M.D., Ph.D.
Role: PI (0% effort)
UTHealth Cancer Genomics Core
$10,000/year direct costs
Dissect osteosarcoma pathological mechanisms by patient-specific iPSC approaches
PI: Dung-Fang Lee, Ph.D.
Role: PI (15% effort)
$475,000/year direct costs
Dissecting the Biology and Therapeutic Vulnerabilities of RB1-Mutant Osteosarcoma Using RB iPSCs
PI: Dung-Fang Lee, Ph.D.
Role: PI (15% effort)
Rolanette and Berdon Lawrence Bone Disease Program of Texas
$45,000/year direct costs
Modeling p53 mutant-associated cancer with LFS patient-derived iPSCs
P.I.: Dung-Fang Lee, Ph.D.
Role: PI (30% effort)
R00 CA181496
$160,164/year direct costs
Modeling p53 mutant-associated cancer with LFS patient-derived iPSCs
P.I.: Dung-Fang Lee, Ph.D.
Role: PI (100% effort)
K99 CA181496
$101,440/year direct costs



Undergraduate Education
1. Lee DF, Chen CC, Hsu TA, Juang JL. A baculovirus superinfection system: efficient vehicle for gene transfer into Drosophila S2 cells. J Virol. 74(24):11873-80, 2000.
Graduate Education
2. Yang DH, Wen Y, Su LK, Xia W, Wang SC, Zhang S, Gan L, Lee DF, Spohn B, Frey JA, Hortobagyi GN, Hung MC. A delayed chemically induced tumorigenesis in Brca2 mutant mice. Oncogene. 23(10):1896-901, 2004.
3. Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY, Zou Y, Bao S, Hanada N, Saso H, Kobayashi R, Hung MC. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell. 117(2):225-37, 2004.
4. Xia W, Chen JS, Zhou X, Sun PR, Lee DF, Liao Y, Zhou BP, Hung MC. Phosphorylation /cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res. 10(11):3815-24, 2004.
5. Wang SC, Lien HC, Xia W, Chen IF, Lo HW, Wang Z, Ali-Seyed M, Lee DF, Bartholomeusz G, Ou-Yang F, Giri DK, Hung MC. Binding at and transactivaiton of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell. 6(3):251-61, 2004.
6. Shao R, Lee DF, Wen Y, Ding Y, Xia W, Ping B, Yagita H, Spohn B, Hung MC. E1A sensitizes cancer cells to TRAIL-induced apoptosis through enhancement of caspase activation. Mol Cancer Res. 3(4):219-26, 2005.
7. Ding Q, Xia W, Liu JC, Yang JY, Lee DF, Xia J, Bartholomeusz G, Li Y, Pan Y, Li Z, Bargou RC, Qin J, Lai CC, Tsai FJ, Tsai CH, Hung MC. Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell. 19(2):159-70, 2005.
8. Lin KA, Chen JH, Lee DF, Lin LY. Alkaline induces metallothionein gene expression and potentiates cell proliferation in Chinese hamster ovary cells. J Cell Physiol. 205(3): 428-36, 2005.
9. Giri DK, Ali-Seyed M, Li LY, Lee DF, Ling P, Bartholomeusz G, Wang SC, Hung MC. Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor. Mol Cell Biol. 25(24):11005-18, 2005.
10. Ping B, He X, Xia W, Lee DF, Wei Y, Yu D, Mills G, Shi D, Hung MC. Cytoplasmic expression of p21CIP1/WAF1 is correlated with IKKbeta overexpression in human breast cancers. Int J Oncol. 29(5):1103-10, 2006.
11. Ding Q, He X, Hsu JM, Xia W, Chen CT, Li LY, Lee DF, Liu JC, Zhong Q, Wang X, Hung MC. Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol. 27(11):4006-17, 2007.
12. Ding Q, He X, Xia W, Hsu JM, Chen CT, Li LY, Lee DF, Liu JC, Hung MC. Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer. Cancer Res. 67(10):4564-71, 2007.
13. Lee DF, Kuo HP, Chen CT, Hsu JM, Chou CK, Wei Y, Sun, HL, Li LY, Huang WC, He X, Ping B, Hung JY, Lai CC, Ding Q, Su JL, Yang JY, Sahin AA, Hortobagyi GN, Tsai FJ, Tsai CH, Hung MC. IKKbeta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell. 130(3):440-55, 2007.
14. Lee DF and Hung MC. All roads lead to mTOR: Integrating inflammation to tumor angiogenesis. Cell Cycle. 6(24):3011-4, 2007.
15. Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, Lang JY, Lai CC, Chang CJ, Huang WC, Huang H, Kuo HP, Lee DF, Li LY, Lien HC, Cheng X, Chang KJ, Hsiao CD, Tsai FJ, Tsai CH, Sahin AA, Muller WJ, Mills GB, Yu D, Hortobagyi GN, Hung MC. “ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation.” Nat Cell Biol. 10(2):138-48, 2008.
16. Yen CJ, Izzo JG, Lee DF, Guha S, Wei Y, Wu TT, Chen CT, Kuo HP, Hsu JM, Sun HL, Chou CK, Buttar NS, Wang KK, Huang P, Ajani J, Hung MC. Bile salt exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett’s-associated esophageal adenocarcinoma. Cancer Res. 68(8):2632-40, 2008.
17. Ding Q, Huo L, Yang JY, Xia W, Wei Y, Liao Y, Chang CJ, Yang Y, Lai CC, Lee DF, Yen CJ, Chen YJ, Hsu JM, Kuo HP, Lin CY, Tsai FJ, Li LY, Tsai CH, Hung MC. Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer Res. 68(15):6109-17, 2008.
18. Lee DF and Hung MC. Advances in targeting IKK and IKK-related kinases for cancer therapy. Clin Cancer Res. 14(18):5656-62, 2008.
19. Lee DF, Kuo HP, Chen CT, Wei Y, Chou CK, Hung JY, Yen CJ, Hung MC. IKKbeta suppression of TSC1 function links the mTOR pathway with insulin resistance. Int J Mol Med. 22(5):633-8, 2008.
20. Chou CK, Lee DF, Sun HL, Li LY, Lin CY, Huang WC, Hsu JM, Kuo HP, Yamaguchi H, Wang YN, Liu M, Wu HY, Liao PC, Yen CJ, Hung MC. The suppression of MAD1 by AKT-mediated phosphorylation activates MAD1 target genes transcription. Mol Carcinog. 48(11):1048-58, 2009.
21. Kuo HP, Lee DF, Xia W, Lai CC, Li LY, Hung MC. (2009). Phosphorylation of ARD1 by IKKbeta contributes to its destabilization and degradation. Biochem Biophys Res Commun. 389(1):156-61, 2009.
22. Kuo HP, Lee DF, Xia W, Wei Y, Hung MC. TNFalpha induces HIF-1alpha expression through activation of IKKbeta. Biochem Biophys Res Commun. 389(4):640-4.
23. Lee DF, Kuo HP, Liu M, Chou CK, Xia W, Du Y, Shen J, Huo L, Chen CT, Hsu MC, Li CW, Ding Q, Liao TL, Lai CC, Lin AC, Chang YH, Tsai SF, Li LY, Hung MC. KEAP1 E3 ligase-mediated down regulation of NF-KappaB signaling by targeting IKKbeta. Mol Cell. 36(1):131-40, 2009.
24. Kuo HP, Lee DF, Chen CT, Liu M, Chou CK, Lee HJ, Du Y, Xie X, Wei Y, Xia W, Weihua Z, Yang JY, Yen CJ, Huang TH, Tan M, Xing G, Zhao Y, Lin CH, Tsai SF, Fidler IJ, Hung MC. ARD1 stabilization of TSC2 suppresses tumorigenesis through the mTOR signaling pathway. Sci Singal. 3(108):ra9, 2010.
25. Tsai SY, Clavel C, Kim S, Ang YS, Grisanti L, Lee DF, Kelley K, Rendl M. Oct4 and Klf4 reprogram dermal papilla cells into induced pluripotent stem cells. Stem Cells. 28(2):221-8, 2010.
26. Carvajal-Vergara X, Sevilla A, D'Souza SL, Ang YS, Schaniel C, Lee DF, Yang L, Kaplan AD, Adler ED, Rozov R, Ge Y, Cohen N, Edelmann LJ, Chang B, Waghray A, Su J, Pardo S, Lichtenbelt KD, Tartaglia M, Gelb BD, Lemischka IR. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature. 465(7299):808-12, 2010.
27. Schaniel C, Lee DF, Lemischka IR. Exploration of self-renewal and pluripotency in ES cells using RNAi. Method Enzymol. 477:351-65, 2010.
28. Zhao R, Yeung SC, Chen J, Iwakuma T, Su CH, Chen B, Qu C, Zhang F, Chen YT, Lin YL, Lee DF, Jin F, Zhu R, Shaikenov T, Sarbassov D, Sahin A, Wang H, Wang H, Lai CC, Tsai FJ, Lozano G, Lee MH. Subunit 6 of the COP9 signalsome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancer. J Clin Invest. 121(3):851-65, 2011.
29. Aguilo F, Avagyan S, Labar AS, Sevilla A, Lee DF, Kumar P, Lemischka IR, Zhou BY, Snoeck HW. Prdm16 is physiological regulator of hematopoietic stem cells. Blood. 117(9):5057-66, 2011.
30. Ang YS, Tsai SY, Lee DF, Monk J, Su J, Ratnakumar K, Ding J, Ge Y, Darr H, Chang B, Wang J, Rendl M, Bernstein E, Schaniel C, Lemischka IR. Wdr5 mediates self-renewal and reprogramming via the embryonic stem cell core transcriptional network. Cell. 145(2):183-97, 2011.
31. Tsai SY, Bouwman BA, Ang YS, Kim SJ, Lee DF, Lemischka IR, Rendl M. Single transcription factor reprogramming of hair follicle dermal papilla cells to induced pluripotent stem cells. Stem Cells. 29(6):964-71, 2011.
32. Zhang X, Yalcin S, Lee DF, Yeh TY, Lee SM, Su J, Mungamuri SK, Pimmele P, Kennedy M, Sellers R, Landthaler M, Tuschl T, Chi NW, Lemischka I, Keller G, Ghaffari S. FOXO1 is an essential regulator of pluripotency in human embryonic stem cells. Nat Cell Biol.13(9):1092-9, 2011.
33. Li C, Ao J, Fu J, Lee DF, Xu J, Lonard D, O’Malley BW. Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1. Oncogene. 30(42):4350-64, 2011.
34. Su JL, Cheng X, Yamaguchi H, Chang YW, Hou CF, Lee DF, Ko HW, Hua KT, Wang YN, Hsiao M, Chen PB, Hsu JM, Bast RC Jr, Hortobagyi GN, Hung MC. FOXO3a dependent mechanism of E1A-induced chemosensitization. Cancer Res. 71(21):6878-87, 2011.
35. Ding Q, Chang CJ, Xie X, Xia W, Yang JY, Wang SC, Wang Y, Xia J, Chen L, Cai C, Li H, Yen CJ, Kuo HP, Lee DF, Lang J, Huo L, Cheng X, Chen YJ, Li CW, Jeng LB, Hsu JL, Li LY, Tan A, Curley SA, Ellis LM, Dubois RN, Hung MC. APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis. J Clin Invest. 121(11):4526-36, 2011.
36. Liu M, Lee DF, Chen CT, Yen CJ, Li LY, Lee HJ, Chang CJ, Chang WC, Hsu JM, Kuo HP, Xia W, Wei Y, Chiu PC, Chou CK, Du Y, Dhar D, Karin M, Chen CH, Hung MC. IKKalpha activation of NOTCH links tumorigenesis via FOXA2 suppression. Mol Cell. 45(2):171-84, 2012.
37. Ling J, Kang Y, Zhao R, Xia Q, Lee DF, Chang Z, Peng B, Fleming JB, Wang H, Lemischka IR, Hung MC, Chiao PJ. KrasG12D-Induced IKK2/beta/NF-kappaB Activation by IL-1alpha and p62 Feedforward Loops is Required for Development of Pancreatic Ductal Adenocarcinoma. Cancer Cell. 21(1):105-20, 2012.
38. Wang Y, Ding QQ, Yen CJ, Xia W, Izzo JG, Lang JY, Li CW, Miller SA, Wang X, Lee DF, Hsu JL, Hsu JM, Huo LF, LaBaff AM, Liu DP, Huang TH, Lai CC, Tsai FU, Chang WC, Chen CH, Wu TT, Buttar NS, Wang KK, Wu Y, Wang H, Ajani J, Hung MC. The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell. 21(3):374-87, 2012.
39. Lee DF†, Su J, Sevilla A, Gingold J, Schaniel C, Lemischka IR†. Combining competition assays with genetic complementation strategies to dissect mouse embryonic stem cell self-renewal and pluripotency. Nat Protoc. 7(4):729-48, 2012. (†Corresponding author)
40. Lee DF, Su J, Ang YS, Carvajal-Vergara X, Mulero-Navarro S, Pereira CF, Gingold J, Wang HL, Zhao R, Sevilla A, Darr H, Williamson AJ, Chang B, Niu X, Aguilo F, Flores ER, Sher YP, Hung MC, Whetton AD, Gelb BD, Moore KA, Snoeck HW, Ma'ayan A, Schaniel C, Lemischka IR. Regulation of Embryonic and Induced Pluripotency by Aurora Kinase-p53 Signaling. Cell Stem Cell. 11(2):179-94, 2012.
41. Kuo HP, Wang Z, Lee DF, Iwasaki M, Duque-Afonso J, Wong SH, Lin CH, Figueroa ME, Su J, Lemischka IR, Cleary ML. Epigenetic roles of MLL oncoproteins are dependent on NF-κB. Cancer Cell. 24(4):423-37, 2013.
42. Kim HS, Bernitz J, Lee DF, Lemischka IR. Genomic editing tools to model human disease with isogenic pluripotent stem cells. Stem Cells Dev. 23(22):2673-86, 2014.
43. Gingold JA, Fidalgo M, Guallar D, Lau Z, Sun Z, Zhou H, Faiola F, Huang X, Lee DF, Waghray A, Schaniel C, Felsenfeld DP, Lemischka IR, Wang J. A genome-wide RNAi screen identifies opposing functions of Snail1 and Snail2 on the Nanog dependency of establishing pluripotency. Mol Cell. 56(1):140-52, 2014.
44. Huo L, Li CW, Huang TH, Lam YC, Xia W, Tu C, Chang WC, Hsu JL, Lee DF, Nie L, Yamaguchi H, Wang Y, Lang J, Li LY, Chen CH, Mishra L, Hung MC. Activation of Keap1/Nrf2 signaling pathway by nuclear epidermal growth factor receptor in cancer cells. Am J Transl Res. 6(6):649-63, 2014. 45. Lee DF†, Su J, Kim HS, Chang B, Papatsenko D, Zhao R, Ye Yuan, Gingold J, Xia W, Darr H, Mirzayans R, Hung MC, Schaniel C, Lemischka IR†. Modeling Familial Cancer with Induced Pluripotent Stem Cells. Cell. 161(2):240-54., 2015. (†Corresponding author)
46. Ding J, Huang X, Shao N, Zhou H, Lee DF, Faiola F, Fidalgo M, Guallar D, Saunders A, Shliaha PV, Wang H, Waghray A, Papatsenko D, Sánchez-Priego C, Li D, Yuan Y, Lemischka IR, Shen L, Kelley K, Deng H, Shen X, Wang J. Tex10 Coordinates Epigenetic Control of Super-Enhancer Activity in Pluripotency and Reprogramming. Cell Stem Cell. 16(6):653-68, 2015.
47. Waghray A, Saiz N, Jayaprakash AD, Freire AG, Papatsenko D, Pereira CF, Lee DF, Brosh R, Chang B, Darr H, Gingold J, Kelley K, Schaniel C, Hadjantonakis AK, Lemischka IR. Tbx3 Controls Dappa3 Levels and Exit from Pluripotency toward Mesoderm. Stem Cell Reports. 5(1):97-110, 2015.
48. Gingold JA, Coakley ES, Su J, Lee DF, Lau Z, Zhou H, Felsenfeld DP, Schaniel C, Lemischka IR. Distribution Analyzer, a methodology for identifying and clustering outlier conditions from single-cell distributions, and its application to Nanog reporter RNAi screen. BMC Bioinformatics. 16:225, 2015.
49. Mulero-Navarro S, Sevilla A, Roman AC, Lee DF, D'Souza SL, Pardo S, Riess I, Su J, Cohen N, Schaniel C, Rodriguez NA, Baccarini A, Brown BD, Cavé H, Caye A, Strullu M, Yalcin S, Park CY, Dhandapany PS, Yongchao G, Edelmann L, Bahieg S, Raynal P, Flex E, Tartaglia M, Moore KA, Lemischka IR, Gelb BD. Myeloid Dysregulation in a Human Induced Pluripotent Stem Cell Model of PTPN11-Associated Juvenile Myelomonocytic Leukemia. Cell Rep. 13(3):504-15, 2015.
50. Aguilo F, Zhang F, Sancho A, Fidalgo M, Di Cecilia S, Vashisht A, Lee DF, Chen CH, Rengasamy M, Andino B, Jahouh F, Roman A, Krig SR, Wang R, Zhang W, Wohlschlegel JA, Wang J, Walsh MJ. Coordination of m(6)A mRNA Methylation and Gene Transcriptionby ZFP217 Regulates Pluripotency and Reprogramming. Cell Stem Cell. 17(6):689-704, 2015.
51. Li CW, Xia W, Lim SO, Hsu JL, Huo L, Wu Y, Li LY, Lai CC, Chang SS, Hsu YH, Sun HL, Kim J, Yamaguchi H, Lee DF, Wang H, Wang Y, Chou CK, Hsu JM, Lai YJ, LaBaff AM, Ding Q, Ko HW, Tsai FJ, Tsai CH, Hortobagyi GN, Hung MC. AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation. Cancer Res. 76(6):1451-62, 2016.
52. Lee DF, Walsh MJ, Aguilo F. ZNF217/ZFP217 meets chromatin and RNA. Trends Biochem Sci. 41(12):986-988, 2016.
53. Gingold J, Zhou R, Lemischka IR, Lee DF. Modeling cancer with pluripotent stem cells. Trends Cancer. 2(9):485-494, 2016.
54. Tu J, Huo Z, Gingold J, Zhao R, Shen J, Lee DF. The histogenesis of Ewing sarcoma. Cancer Rep Rev. 1(2): 1, 2017.
55. Lu J, Song G, Tang Q, Yin J, Zou C, Zhao Z, Xie X, Xu H, Huang G, Wang J, Lee DF, Khokha R, Yang H, Shen J. MiR-26a inhibits stem cell-like phenotype and tumor growth of osteosarcoma by targeting Jagged1. Oncogene.12;36(2):231-241, 2017.
56. Freire AG, Waghray A, Soares-da-Silva F, Resende TP, Lee DF, Pereira CF, Nascimento DS, Lemischka IR, Pinto-do-Ó P. Transient HES5 activity instructs mesodermal cells toward a cardiac fate. Stem Cell Reports. 9(1):136-148, 2017.
57. Lin YH, Jewell BE, Gingold J, Lu L, Zhao R, Wang LL, Lee DF. Osteosarcoma: Molecular pathogenesis and iPSC modeling. Trends Mol Med. 23(8):737-755, 2017.
58. Zhou R, Xu A, Gingold J, Strong LC, Zhao R, Lee DF. Li-Fraumeni syndrome disease model: A platform to develop precision cancer therapy targeting oncogenic p53. Trends Pharmacol Sci. 38(10):908-927, 2017.
59. Tu J, Huo Z, Liu M, Wang D, Xu A, Zhou R, Zhu D, Gingold J, Shen J, Zhao R, Lee DF. Generation of human embryonic stem cell line with heterozygous RB1 deletion by CRISPR/Cas9 nickase. Stem Cell Res. 2018 Feb 2;28:29-32.
60. Zhou R, Xu A, Wang D, Zhu D, Mata H, Huo Z, Tu J, Liu M, Mohamed AMT, Jewell BE, Gingold J, Xia W, Rao PH, Hung MC, Zhao R, Lee DF. A homozygous p53 R282W mutant human embryonic stem cell line generated using TALEN-mediated precise gene editing. Stem Cell Res. 2018 Jan 26;27:131-135.
61. Gingold JA, Zhu D, Lee DF, Kaseb A, Chen J. Genomic Profiling and Metabolic Homeostasis in Primary Liver Cancer. Trends Mol Med. 2018 Apr;24(4):395-411.
62. Xu A, Zhou R, Tu J, Huo Z, Zhu D, Wang D, Gingold JA, Mata H, Rao PH, Liu M, Mohamed AMT, Kong CSL, Jewell BE, Xia W, Zhao R, Hung MC, Lee DF. Establishment of a human embryonic stem cell line with homozygous TP53 R248W mutant by TALEN mediated gene editing. Stem Cell Res. 2018 Apr 27;29:215-219.
63. Zhou R, Xu A, Tu J, Liu M, Gingold JA, Zhao R, Lee DF. Modeling osteosarcoma using Li-Fraumeni syndrome patient-derived induced pluripotent stem cells. J Vis Exp. 2018 Jun 13;(136).
64. Liu M, Tu J, Gingold JA, Kong CSL, Lee DF. Cancer in a dish: Progress using stem cells a platform for cancer research. Am J Cancer Res. 2018 Jun 1;8(6):944-954.
65. Zhu D, Kong CSL, Gingold JA, Zhao R, Lee DF. Induced pluripotent stem cells and induced pluripotent cancer cells in cancer disease modeling. Adv Exp Med Biol. 2018;1119:169-183.
66. Kim HS, Yoo S, Zhou R, Xu A, Bernitz JM, Yuan Y, Gomes AM, Daniel MG, Su J, Demicco EG, Zhu J, Moore, KA, Lee DF†, Lemischka IR, Schaniel C†. Oncogenic role of SFRP2 in p53-mutant osteosarcoma development via autocrine and paracrine mechanism. Proc NatlAcad Sci U S A. 2018 Nov 20:115(47):E11128-E11137. (†Corresponding author) 67. Jewell BE, Liu M, Lu L, Zhou R, Tu J, Zhu D, Huo Z, Xu A, Wang D, Mata H, Jin W, Xia W, Rao PH, Zhao R, Hung MC, Wang LL, Lee DF. Generation of an induced pluripotent stem cell line from an individual with a heterozygous RECQL4 mutation. Stem Cell Res. 2018 Dec;33:36-40. 68. Wang D, Luo H, Huo Z, Chen M, Han Z, Hung M, Su B, Li Y, Wang X, Guo X, Xiao H, Lee D, Zhao R, Yang H. Irradiation-induced dynamic changes of gene signatures reveal gain of metastatic ability in nasopharyngeal carcinoma. Am J Cancer Res. 2019 Mar 1;9(3):479-495.
69. Su J, Zhu D, Huo Z, Gingold JA, Ang YS, Tu J, Zhou R, Lin Y, Luo H, Yang H, Zhao R, Schaniel C, Moore KA, Lemischka IR, Lee DF. Genomic Integrity Safeguards Self-Renewal in Embryonic Stem Cells. Cell Rep. 2019 Aug 6;28(6):1400-1409.e4.
70. Wen MH, Xie X, Tu J, Lee DF, Chen TY. Generation of a genetically modified human embryonic stem cells expressing fluorescence tagged ATOX1. Stem Cell Res. 2019 Dec;41:101631.
71. Huo Z, Tu J, Lee DF, Zhao R. Engineering Mutation Clones in Mammalian cells with CRISPR/Cas9. Methods Mol Biol. 2020; 2108:355-369.
72. Li A, Mallik S, Luo H, Jia P, Lee DF†, Zhao Z†. H19, a Long Non-coding RNA, Mediates Transcription Factors and Target Genes through Interference of MicroRNAs in Pan-Cancer. Mol Ther Nucleic Acids. 2020 Sep 4; 21:180-191. (†Corresponding author) 73. Li H, Tu J, Zhao Z, Chen L, Qu Y, Li H, Yao H, Wang X, Lee DF, Shen J, Wen L, Huang G, Xie X. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas. Theranostics. 2020 Jul 25;10(21):9477-9494.
74. Pang LK, Pena M, Zhao R, Lee DF. Modeling of Osteosarcoma with Induced Pluripotent Stem Cells. Stem Cell Res. 2020 Dec;49:102006.
75. Xu A, Huang MF, Zhu D, Gingold JA, Bazer DA, Chang B, Wang D, Lai CC, Lemischka IR, Zhao R, Lee DF. LncRNA H19 Suppresses Osteosarcomagenesis by Regulating snoRNAs and DNA Repair Protein Complexes. Front Genet. 2021 Jan 15;11:611823.
76. Papapetrou EP, Lee DF. Reprogramming and cancer. Stem Cell Res. 2021 Feb 13;52:102249.
77. Sevilla A, Papatsenko D, Mazloom AR, Xu H, Vasileva A, Unwin RD, LeRoy G, Chen EY, Garrett-Bakelman FE, Lee DF, Trinite B, Webb RL, Wang Z, Su J, Gingold J, Melnick A, Garcia BA, Whetton AD, MacArthur BD, Ma'ayan A, Lemischka IR. An Esrrb and Nanog Cell Fate Regulatory Module Controlled by Feed Forward Loop Interactions. Front Cell Dev Biol. 2021 Mar 19;9:630067.
78. Xiong F, Wang R, Lee JH, Li S, Chen SF, Liao Z, Hasani LA, Nguyen PT, Zhu X, Krakowiak J, Lee DF, Han L, Tsai KL, Liu Y, Li W. RNA m6A modification orchestrates a LINE-1-host interaction that facilitates retrotransposition and contributes to long gene vulnerability. Cell Res. 2021 Aug;31(8):861-885.
79. Huang PS, Wen MH, Xie X, Xu A, Lee DF, Chen TY. Generation of a homozygous knock-in human embryonic stem cell line expressing SNAP-tagged SOD1. Stem Cell Res. 2021 Jul;54:102415. 80. Chiang YT, Chien YC, Lin YH, Wu HH, Lee DF†, Yu YL†. The Function of the Mutant p53-R175H in Cancer. Cancers (Basel). 2021 Aug 13;13(16):4088. (†Corresponding author)
81. Jewell BE, Xu A, Zhu D, Huang MF, Lu L, Liu M, Underwood EL, Park JH, Gingold JA, Zhou R, Tu J, Huo Z, Liu Y, Jin W, Chen YH, Xu Y, Chen SH, Rainusso N, Berg NK, Bazer DA, Vellano C, Jones P, Eltzschig HK, Kaipparettu BA, Zhao R, Wang LL, Lee DF. Patient-derived iPSCs Link Elevated Mitochondrial Respiratory Complex I Function toOsteosarcoma in Rothmund-Thomson Syndrome. PLoS Genet. 2021, 17(12): e1009971.
82. Malla S, Prasad Bhattarai D, Groza P, Melguizo-Sanchis D, Atanasoai I, Martinez-Gamero C, Román ÁC, Zhu D, Lee DF, Kutter C, Aguilo F. ZFP207 sustains pluripotency by coordinating OCT4 stability, alternative splicing and RNA export. EMBO Rep. 2022 Jan 17:e53191.
83. Tu J, Huo Z, Yu Y, Zhu D, Xu A, Huang MF, Hu R, Wang R, Gingold JA, Chen YH, Tsai KL, Forcioli-Conti NR, Huang SXL, Webb TR, Bazer DA, Jia P, Yustein JT, Wang LL, Hung MC, Zhao Z, Zhao R, Huff CD, Shen J, Lee DF. Hereditary retinoblastoma iPSC model reveals aberrant spliceosome function drives bone malignancies. Proc Natl Acad Sci U S A. (under revision)
84. Liu M, Xu A, Hung MF, Zhang Y, Hu R, Liu Y, Gingold JA, Chien CS, Hsu CW, Xiong Fm Jia P, Yang YP, Bazer DA, Li W, Aguilo F, Chiou SH, Boles NC, Hung MC, Zhao Z, Zhao R, Lee DF. Rewired m6A epitranscriptomic networks link mutant p53 to neoplastic transformation. Nat Genet. (under revision).